Verisante Technology, Inc. Named Top Technology and Life Sciences Company on the TSX Venture Top 50 2012 Ranking

February 15, 2012 at 7:05 am

 

VANCOUVER, BRITISH COLUMBIA - Verisante Technology, Inc. (TSX-V: VRS, OTCQX: VRSEF, Frankfurt: V3T) (the “Company” or “Verisante”), a leader in cancer detection technology, announced today that the Company has been named this year’s top ranking Technology and Life Sciences Company on the TSX Venture 50.  

The TSX Venture Exchange’s annual list of its top 50 emerging publicly traded companies is a ranking of the strongest performers from five industry sectors.  Verisante ranked number one on the list of top 10 leading Technology and Life Sciences companies for the year.  Companies are selected based on four equally weighted criteria – return on investment, trading activity, market capitalization growth, and analyst coverage.  The results were obtained from data to December 31, 2011.

As the top ranking Technology and Life Sciences Company, Verisante has been invited to attend the TSX Venture 50 Spotlight event on April 3, 2012 in Toronto, with an opportunity to present to an audience comprised of portfolio managers, investment bankers, research analysts and investment advisors.  

“The number one ranking by the TSX Venture Exchange underscores the breakthrough year the Company has had,” said Thomas Braun, President and CEO.  “The approval of Verisante Aura for use in the key Canadian, European and Australian markets and the industry recognition our technologies have recently received demonstrate that we are moving forward on our commitment to helping healthcare providers save lives through the detection of some of the most common forms of cancer.”

Verisante Aura has also recently been awarded Popular Science Magazine’s “Best of What’s New Award” for 2011, and Verisante Core was named one of the top 10 cancer breakthroughs of 2011 by the Canadian Cancer Society.  In addition, the Company was named a finalist for the 2011 Regional Awards for New Technology by the Canadian Manufacturers & Exporters and the National Research Council of Canada. 

About Verisante Technology, Inc.

Verisante is a medical device company committed to commercializing innovative systems for the early detection of cancer. The Verisante Aura™ for skin cancer detection and the Verisante Core™ series for lung, colon and cervical cancer detection utilize a proprietary cancer detection platform while the operating software and probe technology are unique to each device. The cancer detection platform was developed by the BC Cancer Agency and tested and refined at the Skin Care Centre at Vancouver?General Hospital. This exclusive platform technology allows Verisante to develop and offer a range of compact, non-invasive cancer detection devices that offer physicians immediate results for many of the most common cancers.   The Aura™ has been approved for sale in Canada, Europe and Australia. The Core™ has not yet been approved for sale. 

The TSX Venture Exchange has neither approved nor disapproved of the contents of this press release. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release. 

Company Contact:

Thomas Braun, President & CEO
Verisante Technology, Inc.
Telephone: (604) 605-0507
Email: [email protected]
Website:  www.verisante.com  
Youtube:  www.youtube.com/verisante  
Twitter: www.twitter.com/verisante
Facebook: www.facebook.com/verisante

Forward Looking Statements 

This release contains forward-looking statements, including, but not limited to, statements regarding the future commercialization of medical devices, the market demand for these products and the proprietary protections the Company will obtain with regard to the technology, all of which statements are subject to market risks, and the possibility that the Company will not be able to obtain patent protection or obtain sufficient customer demand. These statements are made based upon current expectations and actual results may differ from those projected due to a number of risks and uncertainties.